Literature DB >> 30137184

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed.

E C Smyth1, A Cervantes2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30137184     DOI： 10.1093/annonc/mdy331

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  miR-665 Suppresses the Epithelial-Mesenchymal Transition and Progression of Gastric Cancer by Targeting CRIM1.

Authors:  Kun-Zhe Wu; Chun-Dong Zhang; Cheng Zhang; Jun-Peng Pei; Dong-Qiu Dai
Journal:  Cancer Manag Res       Date:  2020-05-15       Impact factor: 3.989

2.  Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients.

Authors:  Jiali Zhang; Aoran Dong; Shuzhan Li; Xiubao Ren; Xinwei Zhang
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

3.  Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting.

Authors:  Brianna Lauren; Sassan Ostvar; Elisabeth Silver; Myles Ingram; Aaron Oh; Lindsay Kumble; Monika Laszkowska; Jacqueline N Chu; Dawn L Hershman; Gulam Manji; Alfred I Neugut; Chin Hur
Journal:  J Oncol       Date:  2020-02-17       Impact factor: 4.375

4.  Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer.

Authors:  Elizabeth C Smyth; Andrés Cervantes
Journal:  ESMO Open       Date:  2020-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.